Trial Profile
Phase II Trial of Ibrutinib and PD-1 Blockade in High Risk Chronic Lymphocytic Leukemia to Improve Immune Dysfunction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 16 May 2023 Status changed from suspended to discontinued.
- 10 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 10 Nov 2022 Status changed from recruiting to suspended.